Literature DB >> 11526997

Risperidone-associated new-onset diabetes.

D A Wirshing1, J M Pierre, J Eyeler, J Weinbach, W C Wirshing.   

Abstract

BACKGROUND: Weight gain, and its associated complications such as the development of diabetes, is becoming increasingly recognized as an important potential side effect of the novel antipsychotic drugs.
METHODS: Two retrospective cases are described in which patients with schizophrenia developed diabetes while taking the antipsychotic medication risperidone.
RESULTS: Both patients had preexisting risk factors for diabetes and developed insulin resistance in the context of weight gain. Both cases necessitated medical intervention and one patient requires ongoing treatment with insulin.
CONCLUSIONS: Although the exact mechanism of antipsychotic induced diabetes remains obscure, weight gain appears to be a significant risk factor. Careful monitoring of weight and fasting glucoses is recommended for any patient taking novel antipsychotic medications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11526997     DOI: 10.1016/s0006-3223(01)01087-3

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  15 in total

Review 1.  Metabolic consequences of atypical antipsychotic drugs.

Authors:  Harold E Lebovitz
Journal:  Psychiatr Q       Date:  2003

2.  Weight gain and new onset diabetes associated with olanzapine and risperidone.

Authors:  Wildon R Farwell; Timothy E Stump; Jane Wang; Eskinder Tafesse; Gilbert L'Italien; William M Tierney
Journal:  J Gen Intern Med       Date:  2004-12       Impact factor: 5.128

Review 3.  Drug-induced endocrine and metabolic disorders.

Authors:  Ronald C W Ma; Alice P S Kong; Norman Chan; Peter C Y Tong; Juliana C N Chan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 4.  Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?

Authors:  David C Henderson
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 5.  Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Authors:  John W Newcomer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  A Randomized, Controlled Multisite Study of Behavioral Interventions for Veterans with Mental Illness and Antipsychotic Medication-Associated Obesity.

Authors:  Zachary D Erickson; Crystal L Kwan; Hollie A Gelberg; Irina Y Arnold; Valery Chamberlin; Jennifer A Rosen; Chandresh Shah; Charles T Nguyen; Gerhard Hellemann; Dixie R Aragaki; Charles F Kunkel; Melissa M Lewis; Neena Sachinvala; Patrick A Sonza; Joseph M Pierre; Donna Ames
Journal:  J Gen Intern Med       Date:  2017-04       Impact factor: 5.128

Review 7.  First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Authors:  Deanna L Kelly; Robert R Conley; William T Carpenter
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  [Diabetes mellitus as a complication of treatment with atypical neuroleptics. Possible pathomechanisms and treatment recommendations].

Authors:  H Jahn; T Schneider
Journal:  Nervenarzt       Date:  2004-05       Impact factor: 1.214

Review 9.  Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics.

Authors:  John G Csernansky; Emily K Schuchart
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 10.  Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management.

Authors:  Kimberly A Stigler; Marc N Potenza; David J Posey; Christopher J McDougle
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.